A biosimilar version of the widely used eye medication Eylea (aflibercept) developed by Samsung Bioepis will be available in the United States beginning in January 2027, following a settlement agreement with Regeneron. The biosimilar, marketed as Opuviz, received Food and Drug Administration (FDA) approval in 2024 and has already launched in several international markets, offering a potentially more affordable treatment option for patients with retinal diseases.
The agreement resolves patent litigation between the two companies, paving the way for increased competition in the aflibercept market. Biosimilars, which are highly similar to existing biologic drugs, are expected to play a growing role in managing healthcare costs while maintaining treatment standards. This launch represents a significant step toward expanding access to vital therapies for conditions like age-related macular degeneration, diabetic macular edema and retinal vein occlusion.
Opuviz (aflibercept-yszy 2 mg) has demonstrated comparable efficacy and safety to the reference product, Eylea, in clinical trials. According to Thomas Newcomer, vice president and head of U.S. Commercial operations at Samsung Bioepis, “As with ranibizumab biosimilars, aflibercept biosimilars have the potential to significantly improve accessibility and affordability for patients.” He further emphasized that biosimilars can help manage growing treatment demands “with confidence without compromising on clinical standards.”
International Rollout Underway
The launch of Opuviz isn’t limited to the U.S. The biosimilar first became available in the United Kingdom in January 2026, with subsequent launches planned for the rest of Europe in April and other global markets – excluding Korea – in May. This phased rollout allows Samsung Bioepis to establish a global presence for Opuviz and gather real-world evidence to support its long-term use.
The financial terms of the settlement between Samsung Bioepis and Regeneron remain confidential, according to a press release. Though, the agreement allows Samsung Bioepis to bring a cost-competitive alternative to the U.S. Market, potentially benefiting both patients and the healthcare system.
What are Biosimilars and Why Do They Matter?
Biosimilars are not generics. While generic drugs are chemically identical copies of their brand-name counterparts, biosimilars are highly similar, but not identical, to the original biologic drug. Since of the complexity of biologic molecules, demonstrating “similarity” requires extensive analytical testing and clinical studies. The FDA has a rigorous approval process for biosimilars to ensure they meet the same standards of safety and effectiveness as the original biologic.
The introduction of biosimilars like Opuviz is expected to increase competition, driving down prices and making essential medications more accessible. This is particularly crucial for chronic conditions requiring long-term treatment, such as macular degeneration, where the cost of medication can be a significant burden for patients.
The FDA provides detailed information on biosimilar approvals and regulations, emphasizing their commitment to ensuring patient safety and access to affordable medications.
Looking ahead, the availability of Opuviz in the U.S. In January 2027 will mark a new era in the treatment of retinal diseases. The impact of this increased competition on pricing and patient access remains to be seen, but the potential for positive change is significant. Continued monitoring of real-world outcomes and cost savings will be crucial in evaluating the long-term benefits of this biosimilar.
What are your thoughts on the increasing availability of biosimilars? Share your comments below.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your treatment.
